Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Coeptis Therapeutics Holdings (COEP) Equity Average (2021 - 2025)

Coeptis Therapeutics Holdings (COEP) has 5 years of Equity Average data on record, last reported at $9.0 million in Q3 2025.

  • For Q3 2025, Equity Average rose 285.18% year-over-year to $9.0 million; the TTM value through Sep 2025 reached $9.0 million, up 285.18%, while the annual FY2024 figure was $2.1 million, 20.34% down from the prior year.
  • Equity Average reached $9.0 million in Q3 2025 per COEP's latest filing, up from $7.3 million in the prior quarter.
  • Across five years, Equity Average topped out at $9.0 million in Q3 2025 and bottomed at -$8.8 million in Q2 2021.
  • Average Equity Average over 5 years is $1.7 million, with a median of $2.3 million recorded in 2022.
  • Peak YoY movement for Equity Average: plummeted 151.68% in 2024, then soared 3419.86% in 2025.
  • A 5-year view of Equity Average shows it stood at -$1.6 million in 2021, then skyrocketed by 449.35% to $5.6 million in 2022, then crashed by 75.82% to $1.4 million in 2023, then surged by 209.02% to $4.2 million in 2024, then skyrocketed by 115.16% to $9.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Equity Average were $9.0 million in Q3 2025, $7.3 million in Q2 2025, and $5.4 million in Q1 2025.